Amgen Inc v. Bristol Myers Squibb Co

Scott McKeown

Oona Johnstone

Eldora L. Ellison

Steven D. Maslowski

Matthew A. Pearson

Rachel Elsby

Jason Weil

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Amgen challenges Bristol-Myers Squibb's cancer immunotherapy patent, citing a prior clinical trial for anticipation against all 18 treatment method claims.

Bristol-Myers Squibb Co

Amgen Inc

Last Docket Entry Date

Total Docket Entries

IPR2025-00603 | Amgen Inc v. Bristol Myers Squibb Co | Ex Parte

Patent Trial and Appeal Board

Judge	Cases	Inst. Rate	FWD Inv. Rate
Grace K Obermann	600+	55%	66%
Jeffrey N Fredman	100+	74%	85%
Sheridan K Snedden	500+	65%	75%

Name	Ratings
Wolf Greenfield & Sacks	L5 A
Scott McKeown	L5 A
Oona Johnstone	L2 C

Name	Ratings
Sterne Kessler Goldstein & Fox	L5 A
Eldora L. Ellison	L5 E
Akin Gump Strauss Hauer & Feld LLP	L4 C
Steven D. Maslowski	L4 A
Jason Weil	L1 C
Matthew A. Pearson	-- -- --
Rachel Elsby	-- -- --